Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Section 6 of 6

References

220 sources

  1. Abdeen et al. (2026) (opens in a new tab)
  2. Aetna Wegovy precertification policy (2026) (opens in a new tab)
  3. Aggio et al. (2024) (opens in a new tab)
  4. Akbari et al. (2024) (opens in a new tab)
  5. Alaska Medicaid Rezdiffra criteria (2026) (opens in a new tab)
  6. Alp et al. (2025) (opens in a new tab)
  7. Altimmune PERFORMA initiation release (2026) (opens in a new tab)
  8. American Diabetes Association Professional Practice Committee (2026) (opens in a new tab)
  9. Aminian et al. (2021) (opens in a new tab)
  10. Angulo et al. (2015) (opens in a new tab)
  11. Augusto et al. (2026) (opens in a new tab)
  12. Bansal et al. (2026) (opens in a new tab)
  13. Barb et al. (2023) (opens in a new tab)
  14. Barb et al. (2025) (opens in a new tab)
  15. Boubia et al. (2018) (opens in a new tab)
  16. Boursier et al. (2025) (opens in a new tab)
  17. Boyer-Diaz et al. (2021) (opens in a new tab)
  18. Caussy et al. (2025) (opens in a new tab)
  19. CDC FastStats chronic liver disease and cirrhosis (2026) (opens in a new tab)
  20. Chen et al. (2025) (opens in a new tab)
  21. Chen et al. (2026) (opens in a new tab)
  22. Cigna Rezdiffra prior authorization policy (2026) (opens in a new tab)
  23. ClinicalTrials.gov NCT03008070 (opens in a new tab)
  24. ClinicalTrials.gov NCT03008070 API record (opens in a new tab)
  25. ClinicalTrials.gov NCT03008070 results (opens in a new tab)
  26. ClinicalTrials.gov NCT03459079 (opens in a new tab)
  27. ClinicalTrials.gov NCT03459079 results (opens in a new tab)
  28. ClinicalTrials.gov NCT03866369 (opens in a new tab)
  29. ClinicalTrials.gov NCT04849728 (opens in a new tab)
  30. ClinicalTrials.gov NCT04849728 version 1 (opens in a new tab)
  31. ClinicalTrials.gov NCT04849728 version 15 (opens in a new tab)
  32. ClinicalTrials.gov NCT04849728 version 16 (opens in a new tab)
  33. ClinicalTrials.gov NCT05232071 (opens in a new tab)
  34. ClinicalTrials.gov NCT05232071 API record (opens in a new tab)
  35. ClinicalTrials.gov NCT05232071 results (opens in a new tab)
  36. ClinicalTrials.gov NCT06126562 (opens in a new tab)
  37. ClinicalTrials.gov NCT06215716 (opens in a new tab)
  38. ClinicalTrials.gov NCT06318169 (opens in a new tab)
  39. ClinicalTrials.gov NCT06594523 (opens in a new tab)
  40. ClinicalTrials.gov NCT06632444 (opens in a new tab)
  41. ClinicalTrials.gov NCT07165028 (opens in a new tab)
  42. ClinicalTrials.gov NCT07221227 (opens in a new tab)
  43. ClinicalTrials.gov NCT07795164 (opens in a new tab)
  44. Cooreman et al. (2024) (opens in a new tab)
  45. Cusi et al. (2016) (opens in a new tab)
  46. Cusi et al. (2022) (opens in a new tab)
  47. David et al. (2009) (opens in a new tab)
  48. Davison et al. (2020) (opens in a new tab)
  49. Duell et al. (2022) (opens in a new tab)
  50. Dulai et al. (2017) (opens in a new tab)
  51. Estes et al. (2018) (opens in a new tab)
  52. EU Clinical Trials Information System 2023-508248-23-00 (opens in a new tab)
  53. EU Clinical Trials Information System 2025-524385-18-00 (opens in a new tab)
  54. European Association for the Study of the Liver (2024) (opens in a new tab)
  55. European Medicines Agency NASH reflection paper (2024) (opens in a new tab)
  56. FDA (2018) (opens in a new tab)
  57. FDA (2025) (opens in a new tab)
  58. Fishman et al. (2024a) (opens in a new tab)
  59. Fishman et al. (2024b) (opens in a new tab)
  60. Francque et al. (2020) (opens in a new tab)
  61. Francque et al. (2021) (opens in a new tab)
  62. Francque et al. (2026) (opens in a new tab)
  63. Friedman et al. (2018) (opens in a new tab)
  64. Gordon et al. (2020) (opens in a new tab)
  65. Griffel et al. (2023) (opens in a new tab)
  66. GSK efimosfermin Breakthrough Therapy and PRIME designation release (2026) (opens in a new tab)
  67. Guo et al. (2026) (opens in a new tab)
  68. Harrison et al. (2023) (opens in a new tab)
  69. Harrison et al. (2024) (opens in a new tab)
  70. Holleboom et al. (2026) (opens in a new tab)
  71. Huang et al. (2025) (opens in a new tab)
  72. ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023) (opens in a new tab)
  73. ICER Final Policy Recommendations, NASH (2023) (opens in a new tab)
  74. Inventiva AASLD 2025 abstracts release (2025) (opens in a new tab)
  75. Inventiva AASLD 2026 abstracts release (2026) (opens in a new tab)
  76. Inventiva Breakthrough Therapy designation release (2020) (opens in a new tab)
  77. Inventiva clinical development changes release (2023) (opens in a new tab)
  78. Inventiva CTTQ China IND release (2023) (opens in a new tab)
  79. Inventiva CTTQ milestone release (2025) (opens in a new tab)
  80. Inventiva debt and equity financing release (2026) (opens in a new tab)
  81. Inventiva EASL Congress 2026 abstracts release (2026) (opens in a new tab)
  82. Inventiva EASL SLD 2025 abstract release (2025) (opens in a new tab)
  83. Inventiva Fast Track compensated cirrhosis release (2021) (opens in a new tab)
  84. Inventiva Fast Track designation release (2019) (opens in a new tab)
  85. Inventiva fifth NATiV3 DMC release (2024) (opens in a new tab)
  86. Inventiva first half 2022 results announcement (2022) (opens in a new tab)
  87. Inventiva first half 2026 results announcement (2026) (opens in a new tab)
  88. Inventiva Form 20-F (2026) (opens in a new tab)
  89. Inventiva fourth NATiV3 DMC release (2024) (opens in a new tab)
  90. Inventiva full year 2025 results announcement (2026) (opens in a new tab)
  91. Inventiva Hepalys license release (2023) (opens in a new tab)
  92. Inventiva Hepalys phase 1 initiation release (2025) (opens in a new tab)
  93. Inventiva investor and analyst day presentation (2025) (opens in a new tab)
  94. Inventiva LEGEND AASLD late-breaker release (2024) (opens in a new tab)
  95. Inventiva LEGEND protocol (2024) (opens in a new tab)
  96. Inventiva LEGEND statistical analysis plan (2024) (opens in a new tab)
  97. Inventiva LEGEND topline results release (2024) (opens in a new tab)
  98. Inventiva NATiV3 and financial update release (2024) (opens in a new tab)
  99. Inventiva NATiV3 design release (2021) (opens in a new tab)
  100. Inventiva NATiV3 enrollment completion release (2025) (opens in a new tab)
  101. Inventiva NATiV3 initiation release (2021) (opens in a new tab)
  102. Inventiva NATiV3 last patient visit release (2026) (opens in a new tab)
  103. Inventiva NATiV3 screening resumption release (2024) (opens in a new tab)
  104. Inventiva NATiV3 status update release (2023) (opens in a new tab)
  105. Inventiva NATIVE protocol (2019) (opens in a new tab)
  106. Inventiva NATIVE topline results release (2020) (opens in a new tab)
  107. Inventiva Paris MASH 2026 abstracts release (2026) (opens in a new tab)
  108. Inventiva preliminary full year 2023 results announcement (2024) (opens in a new tab)
  109. Inventiva Sino Biopharm license release (2022) (opens in a new tab)
  110. Inventiva structured financing release (2024) (opens in a new tab)
  111. Inventiva third NATiV3 DMC release (2023) (opens in a new tab)
  112. Inventiva third quarter 2025 results announcement (2025) (opens in a new tab)
  113. Inventiva University of Florida trial topline release (2023) (opens in a new tab)
  114. Javanbakht et al. (2023) (opens in a new tab)
  115. Joszt (2024) (opens in a new tab)
  116. Kamata et al. (2023) (opens in a new tab)
  117. Kanwal et al. (2018) (opens in a new tab)
  118. Kanwal et al. (2021) (opens in a new tab)
  119. Kim et al. (2025a) (opens in a new tab)
  120. Kim et al. (2025b) (opens in a new tab)
  121. Lai et al. (2024) (opens in a new tab)
  122. Lassailly et al. (2020) (opens in a new tab)
  123. Lazarus et al. (2025a) (opens in a new tab)
  124. Lazarus et al. (2025b) (opens in a new tab)
  125. Le et al. (2022) (opens in a new tab)
  126. Le et al. (2023) (opens in a new tab)
  127. Le et al. (2025a) (opens in a new tab)
  128. Le et al. (2025b) (opens in a new tab)
  129. Lee et al. (2024) (opens in a new tab)
  130. Lefere et al. (2020) (opens in a new tab)
  131. Lin et al. (2025) (opens in a new tab)
  132. Loomba et al. (2021) (opens in a new tab)
  133. Loomba et al. (2023) (opens in a new tab)
  134. Loomba et al. (2024a) (opens in a new tab)
  135. Loomba et al. (2024b) (opens in a new tab)
  136. Luthra and Sheth (2025) (opens in a new tab)
  137. Madrigal Pharmaceuticals Colorado price disclosure (2026) (opens in a new tab)
  138. Madrigal Pharmaceuticals Connecticut price disclosure, January 2026 (2026) (opens in a new tab)
  139. Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026) (opens in a new tab)
  140. Mahady et al. (2012) (opens in a new tab)
  141. Mangia and Valenti (2025) (opens in a new tab)
  142. Mantovani et al. (2021) (opens in a new tab)
  143. Mantovani et al. (2022a) (opens in a new tab)
  144. Mantovani et al. (2022b) (opens in a new tab)
  145. Marquardt et al. (2026) (opens in a new tab)
  146. McGovern et al. (2026) (opens in a new tab)
  147. Mironova et al. (2026) (opens in a new tab)
  148. Mittal et al. (2024) (opens in a new tab)
  149. NCQA (opens in a new tab)
  150. Newsome et al. (2020) (opens in a new tab)
  151. Ng et al. (2023) (opens in a new tab)
  152. Njei et al. (2026) (opens in a new tab)
  153. Noureddin et al. (2025) (opens in a new tab)
  154. Noureddin et al. (2026) (opens in a new tab)
  155. Novo Nordisk (2026) (opens in a new tab)
  156. Novo Nordisk Akero acquisition completion release (2025) (opens in a new tab)
  157. Novo Nordisk WEGOVY prescribing information (2026) (opens in a new tab)
  158. NovoCare MASH list price (2025) (opens in a new tab)
  159. O'Hara et al. (2020) (opens in a new tab)
  160. PA Health and Wellness resmetirom clinical policy (2025) (opens in a new tab)
  161. Papadimopoulos et al. (2026) (opens in a new tab)
  162. Patel et al. (2025) (opens in a new tab)
  163. Patel et al. (2026) (opens in a new tab)
  164. Payne et al. (2023) (opens in a new tab)
  165. Prime Therapeutics HCSC resmetirom program summary (2026) (opens in a new tab)
  166. Promrat et al. (2010) (opens in a new tab)
  167. Pulaski et al. (2024) (opens in a new tab)
  168. Rautou et al. (2025) (opens in a new tab)
  169. Ravela et al. (2025) (opens in a new tab)
  170. Riazi et al. (2022) (opens in a new tab)
  171. Rinella et al. (2023a) (opens in a new tab)
  172. Rinella et al. (2023b) (opens in a new tab)
  173. Rinella et al. (2026a) (opens in a new tab)
  174. Rinella et al. (2026b) (opens in a new tab)
  175. Roche 89bio merger agreement release (2025) (opens in a new tab)
  176. Roche 89bio tender offer release (2025) (opens in a new tab)
  177. Sabatini and Gastaldelli (2025) (opens in a new tab)
  178. Sagimet Biosciences strategic and corporate updates release (2026) (opens in a new tab)
  179. Sanyal et al. (2010) (opens in a new tab)
  180. Sanyal et al. (2021) (opens in a new tab)
  181. Sanyal et al. (2024) (opens in a new tab)
  182. Sanyal et al. (2025) (opens in a new tab)
  183. Sayiner et al. (2016) (opens in a new tab)
  184. Sayiner et al. (2017) (opens in a new tab)
  185. Schneider et al. (2024) (opens in a new tab)
  186. Shinde et al. (2025) (opens in a new tab)
  187. Shuaibi et al. (2025) (opens in a new tab)
  188. Simon et al. (2021) (opens in a new tab)
  189. Singh et al. (2015) (opens in a new tab)
  190. Souza et al. (2025) (opens in a new tab)
  191. Sterling et al. (2025a) (opens in a new tab)
  192. Sterling et al. (2025b) (opens in a new tab)
  193. Takeda Pharmaceuticals ACTOS prescribing information (2017) (opens in a new tab)
  194. Tan et al. (2022) (opens in a new tab)
  195. Tapper et al. (2023a) (opens in a new tab)
  196. Tapper et al. (2023b) (opens in a new tab)
  197. Taylor et al. (2020) (opens in a new tab)
  198. University of Florida lanifibranor protocol (2022) (opens in a new tab)
  199. Verrastro et al. (2023) (opens in a new tab)
  200. Vilar-Gomez et al. (2015) (opens in a new tab)
  201. Wallace et al. (2025) (opens in a new tab)
  202. Wettstein et al. (2017) (opens in a new tab)
  203. WHO Drug Information (2016) (opens in a new tab)
  204. Wong et al. (2021) (opens in a new tab)
  205. Younossi et al. (2016a) (opens in a new tab)
  206. Younossi et al. (2016b) (opens in a new tab)
  207. Younossi et al. (2017) (opens in a new tab)
  208. Younossi et al. (2019a) (opens in a new tab)
  209. Younossi et al. (2019b) (opens in a new tab)
  210. Younossi et al. (2020) (opens in a new tab)
  211. Younossi et al. (2021) (opens in a new tab)
  212. Younossi et al. (2022) (opens in a new tab)
  213. Younossi et al. (2023) (opens in a new tab)
  214. Younossi et al. (2025a) (opens in a new tab)
  215. Younossi et al. (2025b) (opens in a new tab)
  216. Younossi et al. (2025c) (opens in a new tab)
  217. Younossi et al. (2025d) (opens in a new tab)
  218. Younossi et al. (2026a) (opens in a new tab)
  219. Younossi et al. (2026b) (opens in a new tab)
  220. Younossi et al. (2026c) (opens in a new tab)